MacroGenics’ (NASDAQ:MGNX) Phase 3 trial of margetuximab met its first sequential primary endpoint of progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer. The median PFS of patients...
Cue Biopharma’s (NASDAQ:CUE) IND for CUE-101, an immuno-oncology candidate for human papilloma virus (HPV)-associated cancers, had been accepted by the FDA. The majority of HPV-associated cancers are caused by the HPV16...
Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patient in its pivotal Phase 3 trial of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia (AIHA).
Ceapro’s (TSXV:CZO) two bioprocessing plants in Alberta received a site license from the Health Canada Natural and Non-Prescription Health Products Directorate, which enables the company to fabricate, package, label...
Principia Biopharma (NASDAQ:PRNB) has dosed the first patient in its Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS). Neuroinflammation and an increase in the number of B cells in...
Athersys’ (NASDAQ:ATHX) MultiStem cell therapy for the treatment of acute respiratory distress syndrome (ARDS) has received FDA fast track designation. ARDS is a widespread inflammation of the lungs that can be...
MeiraGTx (NASDAQ:MGTX) reported that AAV-RPE65, its investigational gene therapy for the treatment of retinal dystrophy, met the primary endpoint of safety and tolerability in a Phase 1/2 study, as well as demonstrated...
Homology Medicines’ (NASDAQ:FIXX) received FDA fast track designation for HMI-102, a gene therapy for the treatment of adults with phenylketonuria (PKU), a rare genetic disease affecting metabolism. Individuals with PKU...
PharmaCyte Biotech (OTCQB:PMCB) and its research partner, the University of Northern Colorado, have developed a cannabinoid-activating human cell line for use in its live-cell encapsulation technology for the treatment...
Titan Pharmaceuticals (NASDAQ:TTNP) signed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding patient access to its Probuphine implant for the...
Magenta Therapeutics (NASDAQ:MGTA) reported preliminary data from its Phase 2 trial testing MGTA-456, a hematopoietic stem cell (HSC) therapy, in patients with inherited metabolic disorders. The Phase 2 study is...
Merus (NASDAQ:MRUS) treated the first patient with MCLA-145, a bispecific antibody therapeutic candidate, in its Phase 1 trial for the treatment of solid tumors. MCLA-145 is an immunostimulatory molecule that binds to...
Genetic Technologies (ASX:GTC; NASDAQ:GENE) has validated risk assessment tests for colorectal cancer in individuals with no known pathogenic gene variant, and for breast cancer in individuals who do not have a family...
uniQure (NASDAQ:QURE) reported new data from its Phase 2b trial of hemophilia B candidate, AMT-061, which demonstrated sustained activity six months after administration in three patients. AMT-061 is a therapy that...
The FDA has accepted Esperion’s (NASDAQ:ESPR) NDAs for its bempedoic acid and bempedoic acid-ezetimibe combination tablets for the treatment of elevated low-density lipoprotein cholesterol (LDL-C). Bempedoic acid and...
Zenabis Global (TSXV:ZENA) and Heritage Cannabis (CSE:CANN; OTC:HERTF) signed a supply and services agreement for Zenabis to supply dried cannabis flower to Heritage for the extraction of CBD and THC. The term sheet...
Biohaven Pharmaceutical Holding (NYSE:BHVN) reported new data from its Phase 2/3 trial of rimegepant, and orally-dosed calcitonin gene-related peptide (CGRP) antagonist, for the prevention of migraines. During the third...
Alder BioPharma (NASDAQ:ALDR) reported new data from its Phase 3 trial of eptinezumab, a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP), for the prevention of migraines. Nearly 60% of patients...
The Chinese Patent Office issued a notice of acceptance to Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) for a patent application about its multi-wavelength photodynamic therapy (PDT). The patent validates the...
Canopy Growth (TSX:WEED; NYSE:CGC) unveiled Spectrum Therapeutics, a new global brand that will encompass all of the company’s ongoing commercial medical and clinical research operations. These include Spectrum...
The FDA has accepted Profound Medical’s (TSX:PRN; OTCQX:PRFMF) 510(k) application for premarket clearance of TULSA-PRO, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and...